CTIS2024-512321-84-00招募中1 期
Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial (TRACE)
Klinikum der Universitaet Muenchen AöR0 个研究点目标入组 111 人开始时间: 2024年5月28日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 65+（—）
- 性别
- All
入选标准
- •Adult or paediatric patients (>2 months of age) after HSCT (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection, refractory to standard antiviral treatment for two weeks (defined as =1 log decrease in viral load over two weeks) as confirmed by quantitative blood PCR analysis, Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection, Written informed consent given (patient or legal representative)
排除标准
- •Acute GvHD > grade II or extensive chronic GvHD at time of IMP transfer, Female patient who is pregnant or breast-feeding, or adult of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8) Note: women of childbearing potential must have a negative serum pregnancy test at study entry, Known hypersensitivity to iron dextran, Patients unwilling or unable to comply with the protocol or unable to give informed consent, Treatment with steroids (>1 mg/kg Prednisone equivalent) at Screening, Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. In case of T-cell depleted HSCT, a prescheduled prophylactic DLI =3 x 10^5 T cells/kg BW is not considered an exclusion criteria., Organ dysfunction or failure as determined by Karnofsky (age >16 years) or Lansky (age =16 years) score =30%, Concomitant enrolment in another clinical trial interfering with the endpoints of this study, Any medical condition which could compromise participation in the study according to the investigator’s assessment, Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study, Second line or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab from Screening until 8 weeks after IMP infusion or prophylactic treatment other than Aciclovir or Letermovir throughout the study except approved by sponsor, Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test
研究者
相似试验
进行中（未招募）
1 期
Treatment of viral infections after stem cell Transplantation with specific immune cellschemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantationEUCTR2018-000853-29-ESKlinikum der Universität München149
进行中（未招募）
1 期
Treatment of viral infections after stem cell Transplantation with specific immune cellschemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantationEUCTR2018-000853-29-FRKlinikum der Universität München149
进行中（未招募）
1 期
Treatment of viral infections after stem cell transplantation with specific immune cellsChemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10067859Term: Allogenic stem cell transplantationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.1Level: PTClassification code 10011831Term: Cytomegalovirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10060931Term: Adenovirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10015108Term: Epstein-Barr virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-000853-29-DEKlinikum der Universität München111
招募中
3 期
Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trialvirus diseasesvirus infections10047438NL-OMON54824Klinikum der Universität München40
进行中（未招募）
1 期
Treatment of viral infections after stem cell Transplantation with specific immune cellschemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantationMedDRA version: 22.0Level: PTClassification code 10067859Term: Allogenic stem cell transplantationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.1Level: PTClassification code 10011831Term: Cytomegalovirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10060931Term: Adenovirus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 21.1Level: PTClassification code 10015108Term: Epstein-Barr virus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2018-000853-29-BEKlinikum der Universität München111